Evidence map›Paper›PMID 34216379›Full record

ArticleAging clinical and experimental research2021

Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients?

Marcello Covino, Giuseppe De Matteis, Davide Della Polla, Maria Livia Burzo, Marco Maria Pascale, Michele Santoro, Raimondo De Cristofaro, Antonio Gasbarrini, Erica De Candia, Francesco Franceschi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marcello CovinoEmergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Giuseppe De MatteisDepartment of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. giuseppe.dematteis@policlinicogemelli.it.ORCID http://orcid.org/0000-0003-2982-3951
Davide Della PollaEmergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Maria Livia BurzoEmergency Department, Ospedale Generale M.G. Vannini, Istituto Figlie di San Camillo, Rome, Italy.
Marco Maria PascaleEmergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Michele SantoroEmergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Raimondo De CristofaroUniversità Cattolica del Sacro Cuore, Roma, Italia.
Antonio GasbarriniUniversità Cattolica del Sacro Cuore, Roma, Italia.
Erica De CandiaUniversità Cattolica del Sacro Cuore, Roma, Italia.
Francesco FranceschiEmergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Università Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients hospitalized with COVID-19 experienced an increased risk of venous thromboembolism.

aimsTo evaluate the effect of chronic oral anticoagulation (OAC) therapy, both with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), on prognosis of COVID-19 older patients.

methodsSingle-center prospective study conducted in the Emergency Department (ED) of a teaching hospital, referral center for COVID-19 in central Italy. We evaluated all the patients ≥ 65 years, consecutively admitted to our ED for confirmed COVID-19. We compared the clinical outcome of those who were on chronic OAC at ED admission with those who did not, using a propensity score matched paired cohort of controls. The primary study endpoint was all-cause in-hospital death. Patients were matched for age, sex, clinical comorbidities, and clinical severity at presentation (based on NEWS ≥ 6). Study parameters were assessed for association to all-cause in-hospital death by a multivariate Cox regression analysis to identify independent risk factor for survival.

resultsAlthough overall mortality was slightly higher for anticoagulated patients compared to controls (63.3% vs 43.5%, p = 0.012), the multivariate adjusted hazard ratio (HR) for death was not significant (HR = 1.56 [0.78-3.12]; p = 0.208). Both DOACs (HR 1.46 [0.73-2.92]; p = 0.283) and VKAs (HR 1.14 [0.48-2.73]; p = 0.761) alone did not affect overall survival in our cohort.

conclusionsAmong older patients hospitalized for COVID-19, chronic OAC therapy was not associated with a reduced risk of in-hospital death. Moreover, our data suggest similar outcome both for patients on VKAs or in patients on DOACs.

Indexed as

COVID-19Administration, OralAnticoagulantsHospital MortalityHumansItalyProspective StudiesRetrospective StudiesSARS-CoV-2Vitamin KAnticoagulantsVitamin KCOVID-19Direct oral anticoagulantsOlder patientsOral anticoagulationVitamin k antagonists

Identifiers

PMID34216379
PMCPMC8254066
OpenAlexW3176436358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.